Company Filing History:
Years Active: 1997
Title: The Innovations of Robert A. Padich
Introduction
Robert A. Padich is an accomplished inventor based in Mason, OH (US). He has made significant contributions to the field of pharmacology, particularly in the treatment of obsessive-compulsive disorders (OCD). His innovative work has led to the development of a unique compound that targets serotonin receptors, providing new avenues for treatment.
Latest Patents
Robert A. Padich holds a patent for the "Treatment of obsessive-compulsive disorders with 5-HT.sub.2 antagonists." This invention focuses on the use of 5-HT.sub.2 antagonists as agents in treating OCD. The specific compound he has developed, (+)-.alpha.-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidine methanol, is a member of a class of N-aralkyl piperidinemethanol derivatives. These compounds are recognized as potent and selective inhibitors of serotonin binding at the 5-HT.sub.2 receptor site.
Career Highlights
Robert A. Padich is associated with Merrell Pharmaceuticals, Inc., where he has been instrumental in advancing research and development in psychiatric medications. His work has not only contributed to scientific knowledge but has also aimed to improve the quality of life for individuals suffering from OCD.
Collaborations
Throughout his career, Robert has collaborated with notable colleagues, including Christopher J. Schmidt and John H. Kehne. These partnerships have fostered a collaborative environment that enhances innovation and research outcomes.
Conclusion
Robert A. Padich's contributions to the field of pharmacology, particularly in the treatment of OCD, highlight his role as a significant inventor. His innovative approaches and collaborations continue to pave the way for advancements in mental health treatment.